Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 169

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

A Novel Hypoxia-Inducible Factor−Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial

Open access
Brigandi, Richard A., Johnson, Brendan, Oei, Coreen, Westerman, Mark, Olbina, Gordana, de Zoysa, Janak, Roger, Simon D., Sahay, Manisha, Cross, Nicholas, McMahon, Lawrence, Guptha, Veerabhadra, Smolyarchuk, Elena A., Singh, Narinder, Russ, Steven F., Kumar, Sanjay, Borsukov, Alexey V., Marasaev, Vyacheslav V., Prasad, Gullipalli, Timokhovskaya, Galina Y., Kolmakova, Elena V., Dobronravov, Vladimir A., Zakharova, Elena V., Abraham, Georgi, Packham, David, Zateyshchikov, Dmitry A., Arutyunov, Gregory P., Volgina, Galina V., Lipatov, Kirill S., Perlin, Dmitry V., Cooper, Bruce, Kumar Saha, Tarun, Zagrebelnaya, Olga A., Mehta, Kalpana S., Koziolova, Natalya A., Fassett, Rob, Alexeeva, Narina P., Lysenko, Lidia V. · 2016 · American Journal of Kidney Diseases

Abstract

BACKGROUND: Anemia associated with chronic kidney disease (CKD) often requires treatment with recombinant human erythropoietin (EPO). Hypoxia-inducible factor-prolyl hydroxylase inhibitors (PHIs) stimulate endogenous EPO synthesis and induce effective erythropoiesis by non-EPO effects. GSK1278863 is an orally administered small-molecule PHI. STUDY DESIGN: Multicenter, single-blind, randomized, placebo-controlled, parallel-group study. SETTING & PARTICIPANTS: Anemic non-dialysis-dependent patients with CKD stages 3-5 (CKD-3/4/5 group; n=70) and anemic hemodialysis patients with CKD stage 5D (CKD-5D group; n=37). INTERVENTIONS: Patients with CKD-3/4/5 received placebo or GSK1278863 (10, 25, 50, or 100mg), and patients with CKD-5D received placebo or GSK1278863 (10 or 25mg) once daily for 28 days. OUTCOMES & MEASUREMENTS: Primary pharmacokinetic and pharmacodynamic (increase and response rates in achieving the target hemoglobin [Hb] concentration, plasma EPO concentrations, reticulocyte count, and others]) and safety and tolerability end points were obtained. RESULTS: Both CKD-3/4/5 and CKD-5D populations showed a dose-dependent increase in EPO concentrations and consequent increases in reticulocytes and Hb levels. Percentages of GSK1278863 participants with an Hb level increase > 1.0g/dL (CKD-3/4/5) and >0.5g/dL (CKD-5D) were 63% to 91% and 71% to 89%, respectively. Per-protocol-defined criteria, high rate of increase in Hb level, or high absolute Hb value was the main cause for withdrawal (CKD-3/4/5, 30%; CKD-5D, 22%). A dose-dependent decrease in hepcidin levels and increase in total and unsaturated iron binding were observed in all GSK1278863-treated patients. LIMITATIONS: Sparse pharmacokinetic sampling may have limited covariate characterization. EPO concentrations at the last pharmacodynamic sample (5-6 hours) postdose may not represent peak concentrations, which occurred 8 to 10 hours postdose in previous studies. Patients were not stratified by diabetes status, potentially confounding vascular endothelial growth factor and glucose analyses. CONCLUSIONS: GSK1278863 induced an effective EPO response and stimulated non-EPO mechanisms for erythropoiesis in anemic non-dialysis-dependent and dialysis-dependent patients with CKD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.ajkd.2015.11.021

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 169

Metadata

Authors
Brigandi, R. A., Johnson, B., Oei, C., Westerman, M., Olbina, G., de Zoysa, J., Roger, S. D., Sahay, M., Cross, N., McMahon, L., Guptha, V., Smolyarchuk, E. A., Singh, N., Russ, S. F., Kumar, S., Borsukov, A. V., Marasaev, V. V., Prasad, G., Timokhovskaya, G. Y., Kolmakova, E. V., Dobronravov, V. A., Zakharova, E. V., Abraham, G., Packham, D., Zateyshchikov, D. A., Arutyunov, G. P., Volgina, G. V., Lipatov, K. S., Perlin, D. V., Cooper, B., Kumar Saha, T., Zagrebelnaya, O. A., Mehta, K. S., Koziolova, N. A., Fassett, R., Alexeeva, N. P., & Lysenko, L. V.
Venue
American Journal of Kidney Diseases
Publisher
Elsevier BV
Published
2016-06
Volume
67
Issue
6
Pages
861-871
ISSN
0272-6386 (ISSN-L)
OpenAlex
W2268447664
Cited by
169
References
3
FWCI
19.49
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.